

## **FOR IMMEDIATE RELEASE**

**CONTACT:** Karl Schmidt  
CEO  
Mirador Biomedical  
206-755-5470  
[kschmidt@miradorbiomedical.com](mailto:kschmidt@miradorbiomedical.com)

### **MIRADOR BIOMEDICAL CLOSES \$1.1 MILLION SERIES A ROUND OF FUNDING**

**Seattle, WA - March 19, 2010** – Mirador Biomedical, Inc., developer of the innovative Compass™ family of medical devices, announced today that it has closed a \$1.1 million Series A round of funding. The funding was led by the Washington Research Foundation (WRF Capital) with Summit Capital and individual angel investors participating.

Mirador Biomedical addresses a critical area of healthcare by seeking to improve patient safety and reduce costs associated with preventable medical errors. During critical procedures, medical professionals need more than confidence – they need certainty. Mirador is developing the Compass family of medical devices to provide this certainty through quantitative pressure measurement administered at the point of use.

The first device, the Compass Vascular Access, has been designed to provide quantitative pressure measurements during the insertion of central venous catheters. The Compass Vascular Access is a sterile, inexpensive, single-use device with an incorporated digital display. The device integrates seamlessly with current procedural techniques while providing physicians the added certainty that comes from quantitative blood pressure measurements. Mirador Biomedical will

use the funds to complete device testing, submit a 510(k) application to the FDA, and ramp up commercialization.

“I really liked the way the team identified a market need and then proceeded to design a solution. It turns out that the problem is more common than originally estimated so the clinical uses and potential user base continue to expand,” commented Loretta Little, managing director at WRF Capital. “What impressed me the most during due diligence was the consistent feedback I received from physicians. They instantly saw the Compass’ utility and value for their practice, and wanted to know when it would be available.”

“We are delighted and very fortunate to have the Washington Research Foundation, Summit Capital, and several seasoned medical device private investors support our efforts to bring the Compass family of products to market,” said Karl Schmidt CEO of Mirador Biomedical. “In this economic environment we believe their investment is truly indicative of the value the Compass provides to the patient, the physician and the medical facilities.”

*-End-*

#### **About Mirador Biomedical**

Mirador Biomedical’s team of experienced entrepreneurs and seasoned medical device professionals are partnering with an exceptional group of physicians and scientists to develop innovative, cost effective devices that provide physiological feedback to alleviate doubt and uncertainty during common medical procedures.

Mirador Biomedical is a privately held company founded in 2009 in Seattle, Washington to develop the Compass™ family of medical devices. The lead product, the Compass Vascular Access, is a sterile, inexpensive, single-use device with an incorporated digital display designed to provide quantitative pressure measurements during the insertion of central venous catheters. The device integrates seamlessly with current procedural techniques and enables physicians to simultaneously view their hands, the patient and the pressure without additional cabling, operators or connections. For more information, visit [www.miradorbiomedical.com](http://www.miradorbiomedical.com)